No Data
Citius Oncology Highlights Early LYMPHIR Commercial Traction, Expansion
Express News | Citius Oncology Shares Are Trading Higher. The Company Issued a Commercial Update on the U.S. Launch of LYMPHIR for the Treatment of Cutaneous T-cell Lymphoma
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions With Leading Cutaneous Lymphoma Experts
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA)
terribletrader : do not buy this stock